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ABSTRACT 
Non-invasive insulin delivery systems have been of global interest. The goal of many studies was to optimize suitable delivery formulation capable 
of producing comparable insulin bioavailability and safety that match or supersedes conventional delivery by the invasive subcutaneous (SC) 
injections. Historically, Pfizer marketed the first insulin inhaler Exubera® in 2006 which was later retracted from the market before completing the 
two years. In recent years, Afrezza®, a new inhalator, and Oral-Lyn™, a buccal spray, have been introduced to the market. While Afrezza® lost the 
marketing and distribution support from Sanofi, Oral-Lyn™
Keywords: Oral insulin, Afrezza
 have not secured US Food and Drug Administration (FDA) and the European Medicines 
Agency (EMA) marketing approval yet. Different technologies to improve insulin’s permeation and absorption through different routes are in the 
pipelines. This review discusses several non-invasive strategies that have been appropriately tested and duly approved by the FDA. Other delivery 
systems are in different phases of development, ranging from in vitro studies to phase 3 clinical trials, providing indications towards the prospects 
of next-generation delivery systems. This review covers studies published in the past 10 y using Scopus, Clinicaltrials.gov, PubMed and Google 
scholar databases. The outcomes of this review indicate that the door is still open for more innovative, efficient and convenient non-invasive insulin 
delivery systems than currently available which may take several years before we can see a game changer in the market.  
®, Oral-Lyn™
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The prevalence of diabetes mellitus (DM) which is a metabolic 
disorder is dramatically increasing worldwide, making it one of the 
major causes of morbidity and mortality [1, 2]. In Saudi Arabia, the 
use of antidiabetic medication for type 2 DM patients represents the 
fourth most utilized medication in the country indicating the 
widespread of this condition [3]. All diabetic patients may require 
insulin administration at some point of time. Type 2 DM 
uncontrolled by oral hypoglycaemic drugs, may require having 
insulin added to their therapy regimen [4]. Controlling diabetes with 
subcutaneous (SC) insulin delivery requires multiple daily injections 
which are considered inconvenient for many diabetic patients since 
it can be accompanied by pain, lipodystrophy, tissue damage and 
allergic reactions at the site of injection [5, 6]. Moreover, the method 
of the administration itself makes it inconvenient to perform in 
public places.  
It has been of interest to academic and pharmaceutical industry 
researchers, especially over the past three decades, to look up for an 
alternative to SC insulin injection to achieve better patient 
compliance and disease complications control, hence avoiding 
associated morbidity and mortality rates [7]. Unfortunately, insulin 
has very poor oral bioavailability as it is easily degraded by 
proteolytic enzymes in the gastrointestinal tract and the enterocytes 
of the intestine as well as various peptidases at the brush-border 
membrane [8]. The search for non-invasive delivery systems for 
insulin by optimizing the delivery of insulin had not produced a 
product that can substitute the traditional method of injecting 
insulin subcutaneously. Despite this, there are only two products for 
the non-invasive delivery of insulin available in the market which 
are Afrezza®, a pulmonary inhalation product and Oral-Lyn™
Studies and articles that were published throughout the past 10 y 
were collected from the following databases: Scopus, 
Clinicaltrials.gov, PubMed and Google Scholar. These databases 
can provide access to peer-reviewed literature and information 
about medical studies in human volunteers. Scopus covers a 
different array of research fields including science, health and 
medicine and contains over 22,800 journal titles from over 5,000 
publishers. Clinicaltrials.gov is a resource provided by the U. S. 
National Library of Medicine and contains over 273,004 research 
studies in the USA and in 203 countries. PubMed comprises more 
than 28 million citations for biomedical literature from MEDLINE, 
life science journals, and online books. Google Scholar indexes 
online reviewed journals and books, conference proceedings, 
theses, patents and other scholarly literature from diverse 
disciplines. Clinicaltrials.gov, PubMed, and Google Scholar are free 
to search databases. 
Each database used provides tools for searching and filtration of 
outcomes. On Scopus, and PubMed, searching was done using the 
following terms/sentences: "insulin drug delivery" and "insulin 
delivery systems" with limitations to articles published in the past 
10 y in the English language. Because Google Scholar tends to 
produce a very large number of articles with no option to limit the 
type of the articles, the advance search was used to limit them to the 
keywords present in the article titles only. In addition, 
Clinicaltrials.gov was used to search for the same keywords under 
“other terms” field of advanced search. Also, the advanced search 
was used to implement the years limit to acquire results from 
interventional trials only. 
Publications from literature review were additionally filtered in all 
databases used depending on the abstracts and article titles to 
exclude results limited to invasive routes of insulin administration, 
artificial pancreas, new antidiabetic drugs and glucose monitoring 
techniques.  
Database and outcomes 
, a 
buccal spray. Therefore, the purpose of this review is to 
systematically collect and analyse available literature related to non-
invasive insulin delivery systems to identify both current systems 
and those that are in the pipeline and draw a conclusion regarding 
the future trends in non-invasive systems.  
Systematic literature review 
The number of hits from different databases used are shown in fig. 
1. The lowest number of hits was provided for Google Scholar (81 
for “insulin drug delivery” and 108 hits for “insulin delivery 
systems”) and the largest number of hits was obtained with 
Scopus (1928 for “insulin drug delivery” and 1892 for “insulin 
delivery systems”). 
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Fig. 1: Number of hits obtained by using scopus, PubMed, google scholar and Clinicaltrials.gov with the keywords “insulin drug delivery” 
and “insulin delivery systems” databases, for online publications since 2008 
 
Reviews, clinical trials and research articles used to collect 
information about non-invasive insulin delivery which was 
categorized according to the route of administration. 
Oral delivery 
Oral administration of insulin represents the most convenient route 
and attractive approach to developing systems that are capable of 
protecting insulin and enhancing its absorption [9]. Insulin is a 
peptide of almost negligible bioavailability (1%) when orally 
administered as a conventional solution, due to degradation by 
gastrointestinal protease enzymes, gastric acid inactivation and low 
intestinal membrane permeability [6]. Therefore, it has always been 
a challenge to establish oral formulation using different methods 
and technologies aiming to yield efficient and safe products. The 
following subsections present several approaches:  
Nanoparticles (NPs) 
They are used mainly to enhance protection and targeting of the 
loaded drugs. An in vivo study on N-trimethyl chitosan chloride 
nanoparticles (TMC-NPs) loaded with insulin found that upon 
coating NPs with FQSIYPpIK peptide (FQS), the intestinal epithelium 
cellular uptake of insulin increased more than uncoated NPs [10]. 
FQSIYPpIK (FQS) peptide exhibits high affinity to integrin αvβ3 
receptor which is a transmembrane glycoprotein. FQS-NPs 
promoted serum insulin concentrations, increasing slowly to a 
maximum reached after 4 h of oral administrations, with a 
bioavailability of 7.58% which is 25 times higher than oral free 
insulin of 0.3% bioavailability.  
Another NPs system in which insulin was encapsulated within 
polymeric chitosan chains and covalently cross-linked with the 
chains of polyethylene glycol (PEG) produced rigid and ultrasmall 
(<15 nm) stable NPs over a wide pH range. These produced NPs 
were further conjugated to PenetraMax, a cell-penetrating peptide 
developed by sequence modification of penetration [11]. This 
technique is still within in vitro testing but promising to be adopted 
as a method for protein, peptide and vaccines delivery since this 
model as water-in-oil (W/O) nanoemulsion containing insulin 
achieved an increase in insulin translocation across the Caco-2 cell 
line by 18% compared to oral insulin solution.  
One in vivo study used diabetic adult male Wister rats to administer 
low molecular weight chitosan nanoparticles in which sodium lauryl 
sulfate is used as a micellar former that is concurrent with chitosan-
insulin complex [12]. The results showed acidic pH stability in which 
only 10% of loaded insulin was released and inactivated after 1 h 
incubation period. The preparation showed a significant lowering of 
blood glucose levels (BGLs), however in comparison to the SC insulin 
this reduction was modest. 
A lipid bio-nanoparticle technology for insulin encapsulation into 
hepatic directed vesicles (HDV-I) was studied in a single-blind, 
placebo-controlled trial. HDV-I comprised of hepatocyte targeting 
molecule (HTM) biotin-phosphatidylethanolamine with 1.1 mg of 
HDV-phospholipid filled in gelatin capsules for administration 30 
min prior to each standardized meal. The postprandial plasma 
glucose (PPG) and incremental PPG area under the concentration-
time curve were significantly lower compared to placebo [13] which 
is clinically relevant, but a linear dose-response was not observed. 
The treatments did not result in any untoward effects such as 
hypoglycemic episodes, but a long-term randomized clinical trial is 
required.  
Nanocarrier could be a biopolymer characterized by biodegradation, 
high stability and binding capacity for a loaded drug, no antigenic 
reaction with the immune system and low toxicity [14]. The use of 
egg albumin nanoparticles for oral insulin administration prepared 
by microemulsion crosslinking method has been investigated in 
vitro. Egg albumin nanoparticles released more insulin at neutral pH 
compared to acidic or alkaline pH and this was related to their 
swelling and therefore the diffusibility of insulin. These prepared 
nanoparticles could be further investigated in vivo in a future study.  
Another interesting nanoparticle system of imprinted insulin and 
insulin bound islets was developed using the precipitation 
polymerization method for oral delivery. Biomimetic molecular 
imprinted polymers (MIPs) have robust physical structures, 
biocompatibility, and loading capabilities and can serve as a carrier 
for proteins and peptides including insulin [15]. In vivo investigation 
using male Wistar rats proved the efficacy of MIPs in targeting 
delivery of insulin by pH-sensitive release and variant degree of 
glucose level reduction based on ratio and type polymers used. The 
bioavailability of insulin from the orally administered nanoparticles 
was comparable to the SC insulin injections when the insulin dose 
was 50:1 respectively.  
Another biomimetic technique involves the use of vitamins 
(thiamine and niacin) as a ligand decorating liposomes nanocarriers 
provide targeting to enterocytes since wide receptors for these 
ligands are distributed in intestinal epithelium enhance penetration 
and delivery of insulin [16]. Upon comparison with SC insulin 
injection, vitamin decorated liposomes showed a mild 
hypoglycaemic effect that lasts for nearly 12 h and an oral 
bioavailability of 2.5%. 
Lipopeptide 
A bacillus lipopeptide product called surfactin promotes resistance 
to digestion by trypsin and pepsin with amphiphilic nature that 
gives it a strong biosurfactant action [6]. In vivo studies showed that 
the combination can produce a hypoglycaemic effect with relative 
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bioavailability 12.48% for diabetic mice and 5.97% for non-diabetic 
dogs. Surfactin in acidic media co-precipitates with insulin and 
provide degradation protection, while in basic media the co-
precipitate will re-dissolve and a heteropolymer is formed upon 
surfactin-insulin binding which in turn promotes intestinal 
absorption.  
Insulin chewing gum 
Chewing gum has been used over the world to deliver different 
drugs and molecules like aspirin, dimenhydrinate, nicotine, and 
others. Insulin-containing chewing gum is suggested in which 
mastication drug would be introduced to saliva for absorption 
through the oral mucosa. Vitamin B12 is a large molecule requiring 
an intrinsic factor to be transported and absorbed such as 
haptocorrin, which is also present in saliva. This has been utilized to 
improve insulin absorption from the oral cavity. Vitamin B12 was 
used to coat insulin in the chewing gum to facilitate its absorption 
[17]. In vivo trials on diabetic rats reported a blood glucose 
reduction when introducing vitamin B12-Insulin conjugate higher 
than free insulin as indicated by a 4.7-fold reduction in the area 
under the area under the blood glucose curve. This formulation had 
a fast onset, fewer side effects, improved bioavailability and ease of 
administration while on the other hand it might be associated with 
flatulence, diarrhoea, facial muscle pain and enamel dentures.  
Liposomes 
Liposomes have been indicated for drug delivery through different 
routes showing an enhanced bioavailability especially for orally 
administered lipids and proteins [18, 19]. One study suggested the 
use of liposomes containing phospholipid/botanical cholesterol 
analogs for insulin delivery to improve gastrointestinal stability 
compared to phospholipid/cholesterol liposome. Human 
recombinant insulin was loaded into liposomes containing β-
sitosterol, stigmasterol, lanosterol, and ergosterol and tested in vitro 
and in vivo for comparison. Ergosterol liposomes showed higher 
stability and oral bioavailability than other formulations. The 
optimal compositions were 1:4 and 1:6 molar ratios of 
phospholipid/ergosterol resulting in constant BGL reduction of 50% 
over 3 h in normal rats [18]. 
Another liposomes model of phospholipid/sodium glycocholate 
loaded with recombinant human insulin has been suggested. Sodium 
glycocholate is a bile salt has the advantages of protease enzymes 
inhibition, permeation enhancement, and low cytotoxicity. In vitro 
tests showed a high entrapment efficiency of insulin (30%) and 
upon comparison to other bile salts like sodium deoxycholate and 
sodium taurocholate, sodium glycocholate liposomes showed 
enhanced protection of inulin and hence has the potential for 
providing improved insulin bioavailability [19] and therefore, 
further in vivo tests will be needed.  
Folic acid (FA) was also proposed as a targeting technique for 
insulin-loaded liposomes towards FA receptors which are frequently 
expressed over the GI tract. This will increase the uptake of loaded 
bioactive insulin [20]. In vivo testing on diabetic rats showed that 
FA-Insulin layersomes, prepared by core insulin liposomes coated 
with layer-by-layer oppositely charged polyelectrolytes and FA 
added to provide ligand-receptor targeting, produced 20% relative 
bioavailability compared to SC insulin and a reduction in BGL of 78% 
over 6 h period.  
Hydrogel 
A hydrogel is a three-dimensional hydrophilic polymer that may offer 
protection of loaded protein from digestive enzymes, extending 
residence time in the intestine and enhancing paracellular transport of 
proteins [21]. A hydrogel that is poly (methacrylic acid-graft-ethylene 
glycol) P(MAA-g-EG) microparticles used as a carrier for insulin and 
insulin-transferrin conjugate was evaluated for insulin permeability 
using Caco-2/HT29-MTX as the cellular model. Results revealed that 
the conjugation of insulin with transferrin by its own increased insulin 
transport 7-folds compared to insulin alone because transferrin 
directed insulin to intestinal epithelium through transferrin receptors 
on these cells. The presence of P(MAA-g-EG) microparticles induced a 
14-folds increase in conjugate transportation. 
An in vivo study on the use of polymethacrylic acid-co-N-vinyl 
pyrrolidine P(MAA-co-NVP) hydrogel for oral protein transportation 
using insulin as a model drug showed a loading efficiency greater 
than 85% [22]. At acidic pH, no insulin release was detected while in 
neutral and basic pH rapid release occurred. Prepared copolymeric 
hydrogels composed of N-vinylcaprolactam and methacrylic acid 
monomers by free radical polymerization for oral delivery of insulin. 
The preparation showed an entrapment ratio of 52% for insulin and 
the capability to protect it from the acidic condition while swelling 
and releasing insulin in the basic media, therefore offering an 
opportunity for oral delivery of insulin [23].  
A natural hydrogel comprised of calcium pectinate beads 
(microbeads size ranging between 180 and 220 µm) containing 
insulin was prepared by ionotropic gelation technique with the aid 
of airflow from an air compressor. Insulin release was dependent on 
the phosphate, calcium and pectin concentrations in the 
preparations of the microbeads and the results suggest them to be 
promising carriers for oral delivery of proteins, but further in vivo 
evaluation is recommended [24]. 
Microparticles  
In one study microparticles were prepared by consecutive 
adsorption of oppositely charged chitosan (Ch) and dextran sulfate 
(DS) into insulin-DS microaggregate and were subsequently 
characterized for biocompatibility and biodegradability. This 
produced a highly stable microparticles in acidic pH with no drug 
release until reaching the neutral pH when insulin release starts and 
by pH of 8.0 all insulin would be released [25]. Ch has mucoadhesive 
and epithelium tight junctions opening properties. Hence insulin 
would be protected against denaturation and increased paracellular 
adsorption would result. In vivo studies on healthy Chinchilla male 
rabbits and diabetic male Wistar rats showed hypoglycaemic effects 
and relative bioavailability of 10.7% in comparison to SC insulin 
administration.  
Oral capsules 
Many studies were performed on chitosan due to its mucoadhesive 
property and biodegradability. Insulin oral capsules with the size of 
about 2.5 mm were suggested as potential carriers for oral insulin 
following an in vivo investigation on diabetic rats. The capsules were 
made of chitosan, alginate, and insulin which demonstrated that by 
increasing the insulin dose from 20 to 40 IU, glucose level decreased 
further and sharper from 33.7% to 51.7% of the initial value after 
two hours of administration [26]. 
Chitosan was also used in phytic acid-chitosan capsule preparation 
with the size of 1.68 mm for orally administered insulin. Phytic acid 
is naturally occurring composed of many anions that are cross-
linked with cations of chitosan forming a stable medium for insulin 
encapsulation [27]. In vivo test on diabetic rats showed that orally 
administered capsule of 40 IU/Kg insulin produced more than 50% 
reduction on BGL sustained for more than 24 h, compared with SC 
insulin administration which resulted in sharp blood glucose 
reduction 84.3% in 1 h and gradually vanished within 12 h. 
Another promising enterically coated insulin capsules were studied, 
whereby they would dissolve in the intestine and release the 
mucoadhesive devices (patches) that direct the release of insulin in 
one direction [28]. The devices were prepared by compressing 1:1:2 
ratio of Eudragit® E PO, pectin and sodium carboxymethylcellulose 
polymers, and permeability enhancer (dimethyl palmitoyl ammonio 
propane sulfonate). Biopsy punches were used to obtain 2 mm discs 
from the device for encapsulation into size 9 capsules that were later 
enterically coated with Eudragit®
Enteric microspheres (EMS) in which insulin was loaded, were 
suggested for oral route formulation. Insulin-loaded EMS was prepared 
by O1/O2 emulsion solvent evaporation method. The microspheres 
were composed of hydroxypropyl methylcellulose acetate succinate to 
provide enteric properties, bacitracin (protease inhibitor) to prevent 
 100. In vivo tests on male Wistar 
diabetic and healthy rats show that drug release started at or greater 
than pH of 5 providing a glucose level reduction of 30 to 33% 
sustained for up to 8 h. For human size capsules, a new generation of 
ready to use delayed release vegetable capsules could be used [29].  
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cleavage and unfolding of insulin and sodium oleate for absorption 
enhancement. EMS formulations were administered orally into male 
Wistar diabetic rats after being filled into gelatine capsule. 
Measurements showed no reduction in BGL within the first 2 h then 
intense reduction through 5 h and beyond [30].  
Microemulsions 
Microemulsions have been used for oral delivery of proteins because 
of protection and enhanced absorption. The method is characterized 
by thermodynamic stability and is formed by mixing water, oil, and 
surfactant [31]. Water in oil microemulsion into which insulin-
chitosan nanoparticles were loaded was evaluated. Oral 
administration of this microemulsion to diabetic male Wistar rats 
resulted in significant blood glucose reduction that was maintained 
over 8 h period in comparison to SC inulin injection that causes 
rapid reduction for a period of 2 h only. 
Bucal delivery 
In one study buccal sprays were prepared by adding the proper 
amount of insulin stock solution to two different solutions of 
absorption enhancers, 5% azone and 3% soybean lecithin (SLT) 
yielding a 40 IU of insulin per ml of solutions. Rabbits were used in 
the study since their buccal mucosa is similar to humans by being 
non-keratinized. BGLs measurements showed total decreasing rates 
of 32.1% and 43.5% for sprays with Azone and STL respectively in 
comparison to a control group. The relative bioavailabilities in 
comparison to SC insulin were 16.7% and 22.6% for sprays with 
Azone and STL respectively [5]. These findings support the use of 
SLT to develop a marketed insulin spray.  
A marketed Oral-Lyn™ by Generex biotechnology (Toronto, Canada) 
represents the first buccal spray of metered insulin doses. The 
proprietary device “RapidMist” resembles Ventolin™ inhaler is used 
to spray the liquid formulation of human insulin. Each puff from the 
spray contains 10 units of insulin and only one unit (i.e. 10%) is 
absorbed into blood circulation [32]. Oral-Lyn™ could be used for 
both type 1 and 2 DM with pharmacokinetic characteristics similar 
to rapid-acting insulin [32, 33]. A trial assessed the use of Oral-Lyn™
Buccal mucosa is of low permeability compared to the sublingual 
area but is also characterized by tolerance to sensitizers, rich 
perfusion and absorbed drugs avoid the first-pass metabolism 
encouraging the use of transmucosal delivery of macromolecular 
agents like proteins and peptides [34]. Controlled insulin delivery 
through buccal mucosa required the rate-limiting step to be the 
vehicle rather than the epithelium, hence absorption enhancers 
should be co-administered [5].  
 
for 15 type 1 diabetic patients for dinner time along with regular SC 
insulin in the morning and lunch times indicated a well-tolerated 
spray of fast onset within 5-10 min. and with lesser hypoglycaemic 
episodes [33]. The product has not yet received the Food and Drug 
Administration (FDA) marketing approval but has been marketed in 
some countries like India, Ecuador, Lebanon, and Algeria.  
Pulmonary delivery 
Pulmonary delivery is widely implemented for macro and micro 
drugs delivery due to the large alveolar surface area of 70m2 to 
140m2
Carriers and absorption regulators 
, thin epithelial layer and the short distance between 
epithelium and alveolar blood vessels that is beneficial for effective 
drug absorption [35, 36]. Thus, delivery of insulin through lungs was 
the first method reported as an alternative to SC injections [4, 37].  
Since the lungs are permeable naturally to macromolecules and have low 
enzyme metabolic activity, insulin formulations were modified to 
prolong the absorption via the pulmonary route. Crystallization is one of 
the processes that play a major role in enhancing drugs stability and 
release. Insulin microcrystal powder combined with lactose carrier was 
prepared using crystallization. Upon examination of the hypoglycaemic 
effect of the formulation on diabetic rats, it was found that the powder 
formulation controls BGLs more effectively compared to a solution [38]. 
The bioavailability of the formulation was 15% relative to insulin SC 
injection and this confirms that microcrystal insulin powder can be a 
promising dosage form for insulin delivery. 
A nanoparticulate system was a recently explored method for the 
transmucosal delivery of pharmaceutical molecules for the different 
purpose. Nanoparticles improve the loading capacity of drugs due to 
its high surface to volume ratio. Additionally, they raise the 
absorption of drugs by reducing epithelial resistance to transport. 
By adding natural polymers like chitosan (CS) and chondroitin (CHS) 
‘CS/CHS nanoparticles’ it is believed that the delivery of 
macromolecules through the lungs would improve. One study 
investigated the capacity of CS/CHS nanoparticles to release insulin 
for the respiratory delivery [39]. The results indicated the suitability 
of this application as the formulations remained stable at 4 °C for 
one month and had good insulin release, but further studies would 
be needed to establish the real potential of their application.  
Thiolated polymers ‘thiomers’ which contains thiol group provide 
higher adhesive properties than the regular nonthiolated 
mucoadhesive polymers [40]. This property is due to the formation 
of covalent bonds between the polymer and the mucosal layer by a 
disulfide bridge. Investigation of the thiolated microspheres 
containing insulin showed a greater reduction in BGLs on diabetic 
rabbits with maximum effect was observed at 6 h which was 31.23% 
of the initial glucose level compared to 75.25% for nonthiolated 
microspheres, proving thiolated microspheres ability as a useful 
drug vehicle for the nasal delivery system for insulin. 
Excipients like cellulose derivatives: carboxymethyl cellulose, 
hydroxypropyl cellulose, and hydroxypropyl methylcellulose are 
usually used as binders for tablets manufacturing [41]. However, 
their effect on nasal absorption of peptides can be highly marked 
when formulated as powder and directly applied to the nasal 
mucosa. A study focusing on sodium carboxymethyl cellulose for the 
nasal delivery of insulin using rats showed improved absorption 
compared to insulin solution, which was attributed to a prolonged 
residence time of the powder formulation [42]. 
Also, tetradecyl-ß-D-maltoside (TDM) which is an alkyl glycoside 
surfactant consisting of 12-14 carbon alkyl chain can produce a transient 
enhancement in nasal permeability of peptides. It was mixed with fast-
acting and long-acting insulins and administered as nasal drops to 
hyperglycaemic rats. The results of the experiment revealed that fast-
acting insulin had rapid nasal absorption (Tmax = 15 min), while the 
long-acting insulin, glargine insulin, had prolonged hypoglycaemic effect 
(Tmax = 60 min) which support their use in nasal insulin products 
capable of producing sufficient control of BGLs [43]. 
Cell-penetrating peptides (CPPs) are a class of short polybasic 
and/or amphipathic peptides, having the ability to deliver numerous 
payloads of macromolecules across cell membranes, and have been 
recently studied for the nasal delivery of insulin [44]. Nasal 
absorption of insulin was successfully enhanced when formulated 
with novel penetratin analog “PenetraMax” with bioavailability 
reaching almost 100% relative to SC insulin administration without 
any toxicity or damage to the epithelial membrane. 
Dextran is a class of complexly branched glucan that has various chain 
lengths, good water solubility and generally recognized as a safe 
excipient. To investigate the inhalation performance of dextran-peptide 
formulation, spray-dried insulin and dextran 10 (70% insulin and 30% 
D10) was compared to Exubera®, a dry powder formulation of insulin 
previously approved and marketed for clinical use, in pure-bred female 
beagle dogs [45]. Both formulations produced similar bimodal particle 
size distribution, and the analysis of post insulin blood levels was 
comparable for both powders. Results suggest a promising path for 
dextran-peptide formulation for pulmonary delivery. 
Nasal gel 
In-situ gel system has conceivable application in enhancing delivery and 
controlled release of macromolecules in addition to its capacity to absorb 
an essential amount of biological fluids without dissolving its own 
structure. A thermosensitive in-situ gel was prepared by combining 
chitosan and polyvinyl alcohol for improving the nasal delivery of insulin 
[46]. The release of insulin from the gel was enough to maintain BGLs for 
six hours due to the bioadhesive characteristics of the gel. The maximum 
effect on lowering BGLs in normal rats was at 4 h compared to 1 h with 
SC insulin injection indicating prolonged insulin release that could result 
in lower hypoglycaemic episodes. The relative bioavailability from the 
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gel was 8.8% which was better than the ineffective nasally administered 
insulin solution used for comparison. Nasal delivery of insulin is still 
challenged by the small surface area, metabolic activity, poor permeation 
and clearance [47].  
Insulin inhalation devices 
Exubera® was the first officially approved pulmonary insulin 
product by the FDA in 2006 [48, 49]. The human insulin powder in 
blisters was taken using Exubera® inhaler (fig. 2-a) with the 
available 1 mg and 3 mg doses [4]. Unfortunately, due to the high 
cost and some concerns related to pulmonary functions, the device 
did not achieve its commercial targets and was withdrawn from the 
market by Pfizer Pharmaceuticals in 2007. An approved insulin 
inhalation system by FDA in June 2014 Afrezza® was developed by 
MannKind Corporation (California, United States) and marketed 
Sanofi (Paris, France) since January 2015. The system (fig. 2-b) 
overcame some disadvantages associated with the Exubera® such as 
the inhaler size and the flexibility and convenience of dosing and 
therefore was expected to have better performance in the market. 
The inhaled insulin is introduced in a pocket-size device where 
insulin is adsorbed to fumaryl diketopiperazine, and the micro-
particles are freeze-dried to form dry powder suitable for inhalation 
[50]. It needs approximately 10-14 min to reach maximum serum 
concentration and three hours for almost complete insulin 
absorption [51] and results in less hypoglycaemia [52]. The adverse 
effects associated with Afrezza® use are similar to Exubera® and 
include pulmonary function decline and a slight increase in lung 
cancer incidence although the latter effect was not substantiated 
[52]. Additional concerns included increased risk of acute 
bronchospasm and diabetic ketoacidosis was more common [51]. 
Afrezza® black box warning contraindicates its use in patients with 
chronic pulmonary diseases and mandates prescribers to assess 
patients’ lungs and use spirometry which further limits its appeal. 
Sanofi had withdrawn from the agreement with the MannKind 
corporation to market Afrezza®
 
 and since July 2016, MannKind 
became the sole manufacturer and marketer. Mannkind believes that 
the challenges they have to deal with are limited by Sanofi’s failure 
in marketing strategy including working with insurers and 
globalizing the product by filing for marketing approval in new 
regions. It is dubious if Mannkind will succeed when Sanofi had 
failed in gaining appropriate market share for this product in 
insulins market.  
 
Fig. 2: Drawings of insulin inhalers depicting relative sizes to 
each other and representing (a) Exubera® in the extended 
position, (b) Afrezza® and (c) Dance 501®
With anticipated dose linearity, superior bioavailability and minimal 
side effects, a promising pulmonary device for is Dance 501




Biopharm (Brisbane, California) is currently in phase 2 trial. The 
inhaler itself is based on technology developed and commercialized 
by Aerogen (Galway, Republic of Ireland). It is based on vibrating 
mesh technology combined with flow path to assist the cleaning of 
the drug reservoir. The small handheld device is battery operated 
(fig. 2-c) with an inhaler that delivers the liquid formulation of 
insulin into the lungs [53]. Despite the expected marginal 
advantages of this new insulin delivery system, it is unclear if the 
company will continue to pursue phase 3 trials since previously 
approved insulin inhalation systems did not demonstrate to be 
lucrative in the highly competitive market dominated by the various 
types of SC insulins. 
Transdermal delivery of insulin has been a point of interest as an 
alternative non-invasive administration method [54, 55]. However, 
stratum corneum which is the superficial layer of skin is a big 
challenge as it’s not permeable to allow the transfer of a large 
molecule like insulin [56]. Therefore, many studies were performed 
to overcome this barrier and enhance skin permeation. This was 
examined through in vitro studies and animals and clinical trials. 
Latest penetration enhancement techniques are iontophoresis using 
electrical currents, sonophoresis using ultrasound waves, 
electroporation, microdermabrasion, micro-needles, chemical and 
biochemical enhancers [4]. 
Sonophoresis 
In one study, the ultrasound waves with 40 kHz frequency were 
applied to male albino Wistar rats to deliver insulin for 60 min in 
pulse mode [54]. The results of glucose-lowering were comparable 
to that of SC insulin injection indicating the effectiveness of the used 
technique. Despite the claimed success, the study did not provide 
details about the bioequivalence of insulin which seemed very low 
considering the high dose used with ultrasound (1 ml of IU-100) in 
comparison to SC insulin (0.25 IU/Kg). Additionally, the air 
ultrasonic ceramic transducer producing the waves occupied a 
larger surface area ratio to the total surface area of the rat used 
compared to the anticipated device that will be used on the human.  
Electroporation and iontophoresis 
Electroporation (EP) is another method for enhancing the skin’s 
permeability using an electroporator to induce temporal pores in the 
skin membrane. The pores on the skin of rabbits were induced 
followed by the application of different formulations of insulin [57]. 
Among all investigated formulations, insulin solution with EP had 
the best results when compared to insulin gel having penetration 
enhancers combined with EP. 
Emulgel is a combined formulation of both emulsion and gel in a 
single dosage form that has received attention for topical 
formulation [58]. Emulgel was prepared by combining insulin with 
emu oil as a penetration enhancer and was examined on diabetic 
rabbits. BGLs decreased to 125±5 mg/dl from initially 250±10 mg/dl 
when the formulation is used in combination with iontophoresis. 
The later provided a synergic effect to the permeation enhancing the 
ability of the formulation. 
Microdermabrasion 
Microdermabrasion is known as a facial treatment and cosmetic 
resurfacing technique for the removal of fine lines, scars, and 
wrinkles. One study stated that microdermabrasion can be used for 
disrupting the dermal layer and enhancing the skin permeability for 
transdermal drug delivery [59]. An experiment was performed on 
diabetic hairless rats in which the skin was microdermabraded using 
a Gold Series MegaPeel machine to deliver insulin via transdermal 
reservoir patch. However, removing the stratum corneum using this 
technique did not increase skin permeability to insulin in 
comparison to microdermabrasion that removed full epidermis 
which provided the best results. According to the authors, full 
epidermis removal group had BGL reduction by 144 mg/dL in 3 h 
[59].  
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One of the latest approaches toward insulin delivery includes the 
application of smart patches. The patch contains glucose-responsive 
microneedles that release insulin automatically in response to the 
increase of the BGLs [60]. Each needle had a conical shape with a 
height of 600 μm, base radius of 150 μm and a tip radius of about 10 
μm, which smaller than the smallest insulin needle, therefore 
ensuring painless administration. The painless microneedles hold 
glucose-responsive vesicles with an average diameter of 118 nm. The 
vesicles are filled with insulin and glucose oxidase enzyme. The latter 
causes glucose oxidation in hyperglycemic conditions which triggers 
the dissociation of vesicles followed by insulin release. Streptozotocin-
induced type 1 diabetic mice treated with these patches containing 10 
mg/kg of insulin for each mouse showed a quick decline in BGL to 
nearly 200 mg/dL from approximately 550 mg/dL within 0.5 h and 
maintained a normoglycemic state for approximately 4 h. The authors 
of the work claim that using these smart “closed-loop” patches in 
human can eliminate episodes of hyper and hypoglycaemia. Although 
this approach could really be all in one system (responding on demand 
to increases in glucose levels), it is early to be optimistic for a 
successful application to the human subject.  
Also, transcutaneous delivery is possible through microneedle array 
patches composed of H2O2-responsive polymeric vesicles (PVS) 
similar to the one described above but differs in the polymeric 
materials used (fig. 3). The PVS are self-assembled from 
polyethylene glycol and phenylboronic ester (PBE)-conjugated 
polyserine forming a hollow structure loaded with insulin and 
glucose oxidase (GOx) [61]. The smart delivery of insulin is similar to 
that described by Yu et al., 2015 [60]. The release kinetics of insulin 
can be controlled by adjusting the concentration of GOx. The patches 
were applied to diabetic mice with an equivalent insulin dose of 10 
mg/kg for each mouse reduced glucose levels to 90 mg/dL in one 
hour and maintain it with normal ranges for nearly 5 h, making it a 
well promising method for controlled non-invasive insulin delivery. 
Based on insulin dose used per kg, it appears that a very large 
quantity of insulin would be needed if patches are to be applied in 
clinical trials. This can totally change the ability of the system to 
perform as well as when using mice model since insulin 
concentration and the surface area of the patch will have to be 
changed in a clinical application which can significantly influence 
insulin release kinetics. Furthermore, the duration for insulin 
release from the patches to maintain glucose levels was for only a 
few hours, when you expect to have days of therapy from traditional 
batches. Nevertheless, the concept of an integrated approach to 
having non-invasive insulin “smart” patches that could deliver 
insulin when needed is the kind of systems we should be looking for.  
 
 
Fig. 3: Illustration showing the release process of insulin from a 
polymeric vesicle filled with insulin and glucose oxidase in the 
presence of glucose [60] 
Pectin ‘poly galacturonic acid’ is known for the delivery of drugs to 
the colonic region of the gastrointestinal tract and for the sustained 
release of drugs [62]. Thus, a pectin insulin-containing dermal patch 
formulation can be explored for providing sustained transdermal 
delivery of insulin. The amidated pectin hydrogel insulin matrix 
patches containing insulin doses of 9.57, 16.80 µg/kg showed 
comparable glucose lowering to fast-acting insulin aspart 
administered subcutaneously in diabetic-induced rats, however, no 
sustained release was demonstrated from the investigation. 
One transdermal patch for insulin delivery completed a clinical trial 
(NCT00519623) [63]. Altea Therapeutics was developing a 
transdermal patch called ‘PassPort patch’ that delivers insulin to the 
skin by creating micropores using bursts of thermal energy to 
produce small channels in the surface of the skin. The patch 
completed phase 1 and 2 for type 1 DM successfully and was well 
tolerated with no serious side effects except for mild temporal 
erythema on sites of application. The company was acquired by 
Nitto Denko Corporation (Japan) in 2012 and further development 
into clinical trial phase 3 was not sought for this insulin patch. 
Insulin jet injectors 
Powder needless injection (PNI) is an interesting transdermal delivery 
technique that uses high-speed gas flow to deliver powdered drugs 
into the skin without needles [64]. The aerodynamic properties of the 
device were enhanced by designing an automatic mechanical unit 
containing a valve system in addition to an enlarged de Laval nozzle. 
Two powder formulations of insulin were prepared as raw insulin and 
inorganic salt-carried insulin. The delivering efficiency and 
bioavailability were evaluated by experiments on rabbits, and it was 
found that phosphate-carried insulin powder had better results and 
higher hypoglycaemic effects compared to the raw insulin that was 
almost not effective when delivered by the PNI indicating the 
importance of the phosphate carrier in the delivery of insulin. In 
comparison to SC injection of phosphate-carried insulin solution, the 
PNI delivery efficiency was 72.25% as indicated by the area above the 
blood glucose curve (indicated glucose lowering effect). However, 
although the delivery of insulin is needless, the device might cause skin 
injuries if used improperly, Irritation caused by the device was related 
to many factors including the gas pressure and the nozzle distance and 
this needs to be optimized to be safe to use in practice. In principle, the 
idea is not new to the market, but the available devices use liquid 
insulin rather than powdered insulin. Their wide use has been 
hindered by cost, decreased absorption over the repeated 
administration, pain or bruising at the administration and the need to 
keep the product sterile to stay hygienic [48].  
Glide Pharma developed a solid dose injector (SDI). The system uses a 
spring-powered handheld pen-like actuator to push a rod-like point 
end solid dosage forms [65]. Polysialic acid (PSA), a biodegradable 
natural polymer, has been used with insulin to form more soluble, 
stable and long circulatory half-life solution. In vitro and in vivo tests 
for SC delivery of solid PSA-insulin conjugate used Glide SDI, which 
was formulated to deliver 1 unit of insulin from a rod of 4 mm length. 
Three doses administered to each rat promoted a 100% penetration 
with delayed response throughout the first hour and prolonged 
efficacy that sustained for at least 5 h, and upon comparison with PSA-
insulin solution same hypoglycaemic effect was obtained.  
Rectal administration 
One study suggested rectal administration of insulin condensed 
dimple suppository since secretory degrative enzymes are much 
lower in the rectum than that of the stomach [66]. Insulin was 
condensed in a dimple with Labrasol® as absorption enhancer, then 
it was covered by sealing materials to direct its release toward rectal 
mucosa only and prevent insulin dilution by rectal fluid, hence 
offering a higher concentration gradient and improved absorption. 
In vivo tests, on male Wistar rats with suppositories administered 
into the rectum showed a glucose level reduction of maximum 
22.9±3.2% at 30 min after administration compared to 8.2±5.8% 
when Labrasol®
Chitosan derivatives were also used analog to Labrasol
 was not used. 
® to enhance 
absorption and have been suggested for rectal as well as nasal 
administration. A study compared the effect of the degree of 
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quaternization of N-trimethyl chitosan chloride (TMC) and pH of the 
preparations on insulin absorption [67]. Different insulin (4 IU/ml) 
preparations were formulated with or without a 0.5% w/v of 
chitosan hydrochloride, TMC-L (12.3% quaternization) and TMC-H 
(61.2% quaternization) at pH 4.4 and pH 7.4. Administration of 
solutions to rats rectally by a syringe showed that at pH 4.4 a sharp 
increase in insulin levels peaking at 30 min after administration with 
blood glucose reduction by 38%, 22% and 22% for chitosan 
hydrochloride, TMC-H, and TMC-L respectively. In contrast, only 
TMC-H effectively increased insulin level to max at 22.5 min 
resulting in 29±7% blood glucose reduction at pH 7.4. The study 
demonstrated that not only the degree of quaternization is an 
important determining factor of insulin absorption, but also the 
insolubility of chitosan hydrochloride prevents it from being 
effective as absorption enhancers at pH 7.4. 
DISCUSSION  
Although extensive studies and efforts were carried out to have non-
invasive alternatives to SC insulin injections, their existence is very 
limited as marketed products. An approximate representation of the 
current status and progress towards marketing approval of non-
invasive insulin delivery systems is provided in fig. 4. The analysis of 
published studies indicates that the majority of them are still in vitro 
and in vivo animal studies (about 91%) with slim chances for 
progress into human trials. The percentages of non-invasive insulin 
delivery systems in various clinical trials do not exceed 6%. It is 
even dubious that any of these systems will progress to the 
marketing approval stage. None of the studies in different clinical 
trial phases are considered an oral formulation of insulin for the 
primary purpose of lowering BGLs was successful so far. 
  
 
Fig. 4: Representation of current status of the development of non-invasive insulin delivery systems, *
 
Two of the three products were FDA 
approved 
The issue of enzymatic degradation of insulin and its molecular weight 
impede the absorption of intact insulin molecules. The majority of the 
studies with oral administration of insulin attempted to improve 
bioavailability. In comparison with SC insulin injections, these 
improvements are not much promising since at best the results could 
show the relative bioavailability of up to 10%. With low bioavailability, 
variability can become significant, preventing the utilization of any 
current oral formulation. For example, the HDV-I as clinical trials 
proved its beneficial effect in reducing BGLs postprandially upon co-
administration with oral hypoglycaemic medications, however, it did 
not show dose-response correlation and the reduction was not 
significant enough for diabetic patients to have normal BGLs. This does 
not close the door for a futuristic smart pill technology. The idea of 
having HDV-I administered orally is tempting because unlike the lack 
of adequate glycaemic control of SC insulin injections due to marked 
peripheral hyperinsulinemia, the delivery of insulin directly to 
hepatocytes through the liver portal vein would allow better control of 
postprandial PGLs by directly toppling hepatic glucose production 
while increasing hepatic glucose uptake [13].  
The marketing of Oral-Lyn™ insulin formulation for buccal 
administration using “RapidMist” inhaler is only with limited success 
since it did not secure the marketing approval of the major 
authorities such as the US FDA and the European Medicines Agency 
(EMA). Oral-Lyn™
Exubera® was the first insulin inhalation product to receive FDA 
approval and consists of blisters containing human insulin inhalation 
powder, which are administered using the Exubera® Inhaler. The 
product proved to be a failure resulting in its withdrawal less than two 
years from its launch [34]. This was attributed to being expensive, 
cumbersome, flawed marketing, restriction in its use, poor 
bioavailability and accuracy of the delivered dose. Therefore, it was 
less favourable to both physicians and patients. Nevertheless, 
MannKind Corporation received FDA marketing approval relatively 
recently to commercialize insulin inhalation system Aferrza®, having 
a compact size, unique as an "ultra-ultra" fast insulin, and improved 
bioavailability and dose flexibility in comparison to Exubera® [68]. 
The new product was crumbled by limiting factors despite its 
anticipated wider acceptance including adverse effects similar to 
Exubera® such as a decline in pulmonary function and 
unsubstantiated evidence of a slight increase in lung cancer incidence 
[52]. A further limiting factor to its sales is the need to assess patients’ 
lungs and use spirometry prior to its prescription. The new insulin 
inhalation device Dance 501® (Dance Biopharm Inc.) is currently in 
 administration requires several puffs to deliver 
the dose along with poor bioavailability making it far from ideal for 
diabetic patients. The fast-acting liquid oral insulin is delivered from 
the metered-dose inhaler as fine aerosolized droplets into the buccal 
area for transmucosal absorption deliver with each puff delivering 
an intact unit of insulin each puff. The product is indicated for both 
types of DM along with other SC insulin preparation for further 
glycaemic control according to the Generex Biotechnology 
Corporation, the proprietor of the product. A window of opportunity 
still exists for buccal formulation development that is capable of 
enhancing absorption through permeability enhancers and also 
there is a need to prolong residence time for an adequate amount of 
insulin to be absorbed. Generex company had indicated that it is 
working on a formulation that allows the use of higher insulin 
concentration and improved formulation, but no outcomes have 
been published so far about the success of their attempt. 
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phase 2 trial using non-diabetic patients. The system features of dose 
individualization for each patient along with its handheld small size, 
employs liquid insulin that is expected to produce higher 
bioavailability than the DPIs (e. g. Exubera® and Aferrza®), with a 
lower incidence of coughing [53]. The fact that the second insulin 
inhalation product Afrezza® did not fulfill its promise in gaining 
popularity despite its advantages over Exubera® sheds a lot of doubts 
about the ability of Dance 501® to perform differently. It is unclear 
how any future insulin inhalation system could address the needs of a 
certain diabetic population such as patients having chronic pulmonary 
diseases and smokers or eliminate the need of prescribers to assess 
patients’ lungs functions before these products can be written in the 
prescription forms.  
The focus on the transdermal delivery using “smart” patches could 
eliminate the need for monitoring BGLs as the systems themselves 
deliver bursts of insulin from specially designed vesicles whenever 
glucose levels rise as the case with prandial glucose and hence 
maintaining more consistent glucose levels. Therefore, such a system 
could be of real significance if they are successful in human by 
delivering therapeutic quantity of insulin sufficient for at least one day 
need without causing skin or other untoward effects. The results from 
published in vivo animal studies [60, 61] indicate that a lot of work to 
be done if these smart patches are to work on human subjects, mainly 
dealing with the amount of loaded insulin and the duration of insulin 
release to maintain desired BGLs for an appropriate length of time.  
The fact that currently insulin needles are of large gauge number (28 
to 31) make them almost painless to many patients. SC insulin 
injections are not only reliable with almost 100% bioavailability but 
enjoy a long history of success for both the prescribers and the 
patients to control hyperglycaemic conditions. It is unclear if any 
new non-invasive system will have such popularity in the next 
several years to come.  
CONCLUSION 
Non-invasive insulin delivery systems are offering diabetic patients 
with the alternative to the conventional SC injections. Unfortunately, 
none of the new systems were able to match the SC insulin in terms 
of bioavailability and cost. Because of their relatively short period in 
the market, they have not yet reached the expected popularity 
among patients and prescribing physicians. The search for ultimate 
insulin delivery systems is still challenging and hindered by the high 
cost, poor permeability and bioavailability, instability, adverse 
effects and the difference in diabetic patients’ requirements. The 
most common route for administering drugs has been explored for 
delivering insulin orally, however, it is of dubious efficiency because 
of the inherent challenges associated with enzymatic and digestive 
juices, first pass metabolism and incomplete absorption. The 
different attempts to shield insulin and improve its uptake into the 
systemic circulation through the portal vein have only produced 
modest improvement in the insulin bioavailability and in many cases 
did not show linearity between the administered dose and the 
reduction in the BGLs. Therefore, the oral route remains an open 
area for improving insulin bioavailability, probably with systems 
that are capable of delivering insulin to hepatocytes. A nonorthodox 
approach to dealing with diabetes may be needed to eliminate the 
need for administering insulin altogether and reduce the health-
associated burden. Till then the SC insulin administration using 
microfine insulin needles to reduce associated pain will dominate 
insulin delivery systems for several years to come as indicated by 
the current products in different phases of clinical trials.  
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